Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

NCT02603393 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1053

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: QVA149
DRUG: Tiotropium
DRUG: Salmeterol/fluticasone

Sponsor

Novartis Pharmaceuticals